JPMorgan Starts Seaport Therapeutics (SPTX) at Overweight
JPMorgan analyst Tessa Romero initiates coverage on Seaport Therapeutics (NASDAQ: SPTX) with a Overweight rating and a price target of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
